Cell Transplantation最新文献

{"title":"Hotspots and trends in stem cell therapy for ligament injuries: A bibliometric analysis (2001-2025).","authors":"Xuchao Wang, Junjie Liu, Wenlong Gao","doi":"10.1177/09636897261462233","DOIUrl":"10.1177/09636897261462233","url":null,"abstract":"<p><p>Ligament injuries can lead to lasting instability and early joint degeneration despite rehabilitation or surgery. Stem cell therapies may aid regeneration, but studies are highly variable. Bibliometric analysis can summarize trends, hotspots, and research gaps. We searched the Web of Science Core Collection for English-language original articles on stem cell therapy for ligament injuries from 2001 to 2025 on April 2, 2025, excluding non-original publications. Publication and citation trends were summarized, and co-authorship, co-citation, and keyword networks were mapped using Excel, VOSviewer, CiteSpace, and Bibliometric.com. A total of 599 articles were included, with steadily increasing annual publications. The United States and China were leading contributors, with strong collaboration networks involving major institutions such as the University of Pittsburgh and Zhejiang University. Keyword analyses identified seven main themes spanning mechanisms, clinical translation, tissue engineering, surgery/grafting, injury models, biomechanics, and biomaterials. Recent hotspots included \"inflammation\" and \"artificial ligament\". Stem cell research for ligament injuries is increasingly focused on mechanisms and biomaterials, but evidence is still mainly preclinical and inconsistent. Better comparative clinical studies and standardized, well-defined biomaterial-cell approaches are needed.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261462233"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13309644/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148315885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Three-dimensionally printed mesoporous bioactive glass for craniomaxillofacial bone regeneration: Material evolution, functional mechanisms, and clinical translation.","authors":"Tianqi Wu, Yijie Du, Baofeng Yang, Jinwu Wang","doi":"10.1177/09636897261445514","DOIUrl":"10.1177/09636897261445514","url":null,"abstract":"<p><p>Craniomaxillofacial (CMF) bone defects pose significant regenerative challenges due to complex anatomy and physiological demands. While autologous bone grafting remains the gold standard, it is limited by donor-site morbidity and supply constraints. Mesoporous bioactive glass (MBG), characterized by its ordered nanoporous structure and superior bioactivity, offers a promising alternative. This review systematically analyzes the integration of MBG with 3D printing technologies, including direct ink writing, stereolithography, selective laser sintering, and fused deposition modeling. We critically evaluate physicochemical challenges such as rheological optimization and thermal devitrification while elucidating the \"osteo-immune-vascular\" axis orchestrated by these scaffolds. Specifically, we discuss how ionic dissolution products modulate macrophage polarization, stabilize hypoxia-inducible factor-1α (HIF-1α) to induce CD31ʰⁱEmcnʰⁱ vessel formation, and activate Wnt/β-catenin signaling. Despite promising preclinical data, clinical translation faces hurdles regarding regulatory approval and manufacturing standardization. Future developments in 4D printing, AI-driven inverse topology design, and organ-on-a-chip validation represent a paradigm shift from passive substitution to active regeneration, paving the way for the tissue-engineered reconstruction of complex CMF defects.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261445514"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13319769/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148343914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-course blinatumomab as a bridge-to-transplantation improves the survival of Ph-negative MRD-positive B-ALL.","authors":"Xia Shao, Miao Zhang, Huiying Qiu, Jun Yang, Xinxin Xia, Yu Cai, Yin Tong, Chongmei Huang, Baoxia Dong, Kun Zhou, Liping Wan, Yuhu Feng, Xianmin Song","doi":"10.1177/09636897261466817","DOIUrl":"10.1177/09636897261466817","url":null,"abstract":"<p><p>Post-transplant relapse remains the chief therapeutic challenge in Ph-negative B cell acute lymphoblastic leukemia (Ph^- B-ALL). This retrospective study evaluated whether short-course blinatumomab for measurable resident disease (MRD) eradication could improve transplant outcomes. We compared 23 patients receiving pre-transplant short-course blinatumomab (2-week) for MRD eradication with 46 chemotherapy-only controls. All achieved MRD-negative before allogeneic peripheral blood stem cell transplantation (allo-PBSCT). Only two patients developed grade 2 cytokine release syndrome with blinatumomab. The neutrophil and platelet engraftment times were similar between the two groups. The blinatumomab cohort had a significantly lower 18-month cumulative incidence (CI) of relapse (<i>p</i> = 0.05) and chronic graft-versus-host disease (GVHD) (14.8% <i>vs.</i> 41.8%; <i>p</i> = 0.05), with comparable non-relapse mortality (NRM) (<i>p</i> = 0.98) and 180-day grade II-IV acute GVHD rates (<i>p</i> = 0.93). Consequently, this cohort showed superior 18-month relapse-free survival (RFS) (90.9% <i>vs.</i> 65.2%; HR 0.30, 95% CI 0.09-1.04; <i>p</i> = 0.04), improved 18-month overall survival (OS) (95.7% <i>vs.</i> 81.9%; HR 0.20, 95% CI 0.03-1.71), and a trend toward better GVHD-free and relapse-free survival (GRFS) (74.71% <i>vs.</i> 63.71%; HR 0.64, 95% CI 0.23-1.78). Multivariate analysis confirmed blinatumomab as an independent favorable factor for RFS. In conclusion, short-course blinatumomab as a bridge-to-transplantation could reduce the risk of relapse and improve survival for Ph^- B-ALL patients undergoing allo-PBSCT.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261466817"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13342381/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148396080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amniotic epithelial cells enhance islet engraftment by suppressing early inflammation in intraportal transplantation.","authors":"Kaoru Okada, Kazuaki Tokodai, Miyako Tanaka, Yuki Watanabe, Hitomi Okita, Takako Ito, Masatoshi Saito, Michiaki Unno, Toshio Miki, Masafumi Goto, Takashi Kamei","doi":"10.1177/09636897261464036","DOIUrl":"10.1177/09636897261464036","url":null,"abstract":"<p><p>Amniotic epithelial cells (AECs) have immunomodulatory and anti-inflammatory properties that may improve outcomes in cell transplantation. However, their effect on islet engraftment after intraportal co-transplantation remains unclear. We evaluated the impact of co-transplanting syngeneic 600 islet equivalents (IEQs) with human AECs (hAECs) via the portal vein in a rat streptozotocin-induced diabetes model. The co-transplantation (Co-Tx) group showed normalization of blood glucose levels within 7 days after transplantation, sustained normoglycemia thereafter, and achieved a higher diabetes reversal rate than controls (100% vs. 71.4%, p < 0.01). Serum CXCL1 levels were significantly lower in the Co-Tx group indicating suppression of early inflammatory responses. Thrombin-antithrombin complex (TAT) levels also tended to be lower, raising the possibility of attenuation of the instant blood-mediated inflammatory reaction (IBMIR). In contrast, no significant differences were observed in VEGF levels or intrahepatic microvascular density. Co-transplantation with hAECs enhances islet engraftment likely through suppression of early inflammation, highlighting their potential as an adjunctive cellular therapy in islet transplantation.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261464036"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13305276/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148307296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gelatin sponge loaded with hypoxic human umbilical cord mesenchymal stem cell exosomes promotes healing of enterocutaneous fistula.","authors":"Yankui Liu, Wenwen Yu, Guang Wang, Hongbin Liu","doi":"10.1177/09636897261427905","DOIUrl":"10.1177/09636897261427905","url":null,"abstract":"<p><p>Enterocutaneous fistula (ECF) traditionally relies on surgical treatment and lacks effective therapies to promote tissue regeneration. This study constructed a composite system based on hypoxia-preconditioned human umbilical cord mesenchymal stem cell-derived exosomes loaded onto a gelatin sponge (GS Hypo-Exos), aiming to explore its potential application in ECF treatment. First, systematic characterization of exosomes was performed: transmission electron microscopy, nanoparticle tracking analysis, western blot, and flow cytometry confirmed successful exosome extraction. Material evaluation indicated that the gelatin sponge exhibited high porosity and good biocompatibility. Scanning electron microscopy confirmed successful loading of exosomes onto the sponge surface, and <i>in vitro</i> release experiments showed that GS Hypo-Exos enabled sustained release of VEGF and IGF-1, with release behavior superior to the normoxic control group. Small-animal <i>in vivo</i> imaging further demonstrated that exosome-loaded gelatin sponge could be retained locally at the fistula site for up to 21 days post-surgery. In the Sprague-Dawley rat ECF model, the GS Hypo-Exos treatment group (group C) showed superior healing effects compared with the normoxic exosome group: fistula area and circumference were significantly reduced, and animal weight recovery was the fastest. Serological analysis revealed that this group had the lowest level of inflammatory factor TNF-α and the highest level of anti-inflammatory factor IL-4. Local tissue levels of VEGF and TGF-β1 were significantly increased. Histopathological examination indicated reduced inflammatory cell infiltration and increased collagen fiber proliferation in group C. Regarding molecular mechanisms, real-time quantitative polymerase chain reaction and western blot results consistently showed significantly upregulated expression of the cell proliferation marker Ki67 and markedly downregulated expression of the apoptosis-related protein Caspase-3 in group C. In summary, GS Hypo-Exos effectively promotes structural and functional repair of ECF through synergistic sustained-release delivery and immunomodulation, providing experimental evidence for the development of novel ECF repair strategies.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261427905"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12972546/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147376159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A milestone in liver xenotransplantation: The first 10-gene-edited pig-to-living-human auxiliary transplantation and the road ahead.","authors":"Yinan Zhu, Aizhen Tang, Qin Xiao, Jiulong Hu","doi":"10.1177/09636897251411036","DOIUrl":"10.1177/09636897251411036","url":null,"abstract":"<p><p>The global shortage of human donor livers poses a formidable barrier to treating end-stage liver diseases and unresectable hepatic malignancies, leaving millions of patients without life-saving options each year. While genetically engineered pig-to-human xenotransplantation has achieved significant breakthroughs in cardiac and renal fields, liver xenotransplantation has long lagged due to the liver's intricate metabolic, synthetic, and immunological functions. The recent report by Zhang et al. in the <i>Journal of Hepatology</i>-documenting the world's first successful auxiliary liver xenotransplantation from a 10-gene-edited pig to a living human, with the recipient surviving 171 days-marks a transformative milestone in regenerative medicine. This commentary examines the study's groundbreaking contributions to donor genetic engineering and perioperative clinical management, while critically analyzing the persistent challenge of xenotransplantation-associated thrombotic microangiopathy and outlining future directions to advance clinical translation.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897251411036"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12764749/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145892162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent advances in the discovery, characterization, and therapeutic efficacy of antler stem cells and their secreted extracellular vesicles.","authors":"Jiping Li, Qianqian Guo, Chunyi Li","doi":"10.1177/09636897261495824","DOIUrl":"https://doi.org/10.1177/09636897261495824","url":null,"abstract":"<p><p>Deer antlers are the only mammalian appendage capable of complete regeneration, with antler stem cells (AnSCs) playing a central role in this process. Extracellular vesicles (EVs) secreted by AnSCs function as the key paracrine mediators that mediate the multifaceted biological functions of these stem cells. Herein, we systematically review the research progress in the discovery, characterization, therapeutic applications, and scalable expansion technologies of AnSCs and their EVs. AnSCs exhibit the properties of both embryonic stem cells and mesenchymal stem cells, and their EVs have low immunogenicity and high bioactivity, demonstrating the remarkable application potential in regenerative medicine. Although current studies have elucidated some of their key functions and mechanisms, critical challenges remain for the development of therapeutic agencies, including the standardized procedure of production, establishment of quality control systems, and identification of molecular targets. This review summarizes current advances in AnSCs and their EVs, aiming to provide a new avenue for subsequent clinical translation and industrial application.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261495824"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149171513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of tumor microenvironment composition and metabolism in lymphoid malignancies and therapeutic strategies.","authors":"Siyan Niu, Can Liu, Qi Deng","doi":"10.1177/09636897261449351","DOIUrl":"10.1177/09636897261449351","url":null,"abstract":"<p><p>The tumor microenvironment (TME) plays a significant role in the occurrence, development, and prognosis of lymphomas. The mechanisms of each TME component in lymphoma and related therapeutic strategies are reviewed in this article. In the immune-related TME, regulatory T-cells (Tregs), tumor-associated macrophages (TAMs), and other immune cells mediate immune suppression and evasion. In the non-immune-related TME, cancer-associated fibroblasts (CAFs) and extracellular matrix (ECM) are involved in tumor progression, drug resistance, and immune evasion. In addition, aberrant glucose, amino acid, and lipid metabolism in tumor cells not only sustain their rapid proliferation and survival but also reshape the TME to favor immune escape, thereby worsening patient outcomes. Various treatment strategies targeting the components of the TME and metabolic abnormalities have brought new hope for the treatment of lymphoma. Further in-depth investigation into the intricate crosstalk between the TME and lymphoma cells will be instrumental in developing more effective, personalized precision therapies to improve patient survival.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261449351"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13219950/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148041417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the efficacy of pre-transplant and post-transplant antithymocyte globulin combined with post-transplant cyclophosphamide for graft-<i>versus</i>-host disease prophylaxis in myeloablative haploidentical peripheral blood stem cell transplantation.","authors":"Xuelian Jin, Tian Dong, Jie Ji, Zhigang Liu, Pu Kuang, Jian Li, Yu Wu, Juan Xu, Zerong Wang, Jiajia Zeng, Zilin Xiong, Xinchuan Chen","doi":"10.1177/09636897261454024","DOIUrl":"10.1177/09636897261454024","url":null,"abstract":"<p><p>Although post-transplant cyclophosphamide (PTCy) is widely used to prevent graft-versus-host disease (GVHD), its protective effect remains inadequate in patients undergoing myeloablative haploidentical peripheral blood stem cell transplantation (haplo-PBSCT). We retrospectively evaluated the efficacy of PTCy combined with either pre-transplant or post-transplant antithymocyte globulin (ATG) for GVHD prevention in 114 haplo-PBSCT recipients. The PTCy+FTATG group (n = 74) received ATG at a total dose of 5 mg/kg on days -3 to -1, together with PTCy at 25 mg/kg on days +3 and +4. The PTCy+PTATG group (n = 40) received PTCy at 50 mg/kg on days +3 and +4, followed by ATG at 2.5 mg/kg on day +8. Both univariate and multivariate analyses showed that PTCy+FTATG prophylaxis significantly lowered the risk of grade II-IV acute GVHD (9.5% vs 27.5% [HR 0.24; 95% CI: 0.10-0.59; <i>P</i> = 0.002]) and grade III-IV acute GVHD (5.4% vs 17.5% [HR 0.19; 95% CI: 0.07-0.54; <i>P</i> = 0.002]). The 2-year cumulative incidence of chronic GVHD was 16.7% in the PTCy+FTATG group and 27.5% in the PTCy+PTATG group (<i>P</i> = 0.15). At 2 years, overall survival (OS), progression-free survival (PFS), and graft-versus-host disease-free relapse-free survival (GRFS) were 87.8% vs 72.5% (<i>P</i> = 0.04), 82.2% vs 65.0% (<i>P</i> = 0.03), and 78.1% vs 55.0% (<i>P</i> = 0.005), respectively. These results suggest that half-dose PTCy combined with low-dose pre-transplant ATG may be a promising strategy for GVHD prophylaxis.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261454024"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13227027/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148136785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cdc42-Modified BMSC-Derived exosomes promote acellular nerve allografts to bridge sciatic nerve defects.","authors":"Xin Sui, Guangming Dai, Bo Feng","doi":"10.1177/09636897261455558","DOIUrl":"10.1177/09636897261455558","url":null,"abstract":"<p><p>Peripheral nerve injury (PNI) often results in persistent functional deficits, and current treatments remain suboptimal. This study developed a tissue-engineered graft by integrating Cdc42-modified bone marrow-derived mesenchymal stem cell (BMSC)-derived exosomes (Exos-Cdc42) with an acellular nerve allograft (ANA) and evaluated its therapeutic potential for nerve regeneration and functional recovery. Exosomes were isolated from BMSCs, and Exos-Cdc42 were generated by transfecting these cells with Cdc42 overexpression vectors. In vitro, Exos-Cdc42 significantly enhanced Schwann cell proliferation, migration, and secretion of neurotrophic factor (BDNF, NGF, CNTF), while upregulating repair-associated markers and downregulating myelination-related markers. In vivo, the combination of Exos-Cdc42 and ANA improved functional recovery of the sciatic nerve, as evidenced by higher sciatic functional index scores and increased muscle weight. Histological analyses demonstrated enhanced axonal regeneration and myelination, characterized by thicker myelin sheaths and larger axon diameters. These findings suggest that Exos-Cdc42 enhance the therapeutic efficacy of ANA by promoting Schwann cell-mediated repair responses, representing a promising strategy for peripheral nerve regeneration.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261455558"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13291450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148276228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}